Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Immunol.

Sec. Vaccines and Molecular Therapeutics

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1680732

Decadal advances and future prospects in subunit vaccine development against Streptococcus suis infection

Provisionally accepted
  • Shenzhen Longhua District Central Hospital, Shenzhen, China

The final, formatted version of the article will be published soon.

Streptococcus suis (SS), particularly serotype 2 (SS2), is a significant zoonotic pathogen causing severe disease in swine and humans. High genetic diversity and antibiotic resistance complicate vaccine development. We firstly synthesize the pivotal advances in SS subunit vaccine design over the past ten years, thereby establishing a foundation for guiding future rational vaccine development. Promising candidates, including pS-Lpp-SaoA (delivered via OMVs), SaoA (via live vectors), IgA1 protease, rIde-10, rIde-14009-1, Enolase, 6-GPD, 38-BP-Enol, and multi-antigen formulations (MRP/GAPDH/DLD or SLY/Enolase/Sbp), elicit robust immune responses (high IgG/IgA titers) and confer up to 100% protection against lethal SS2 challenge in murine and porcine models. Cross-protection against heterologous serotypes (e.g., SaoA and Enolase delivered via S. Choleraesuis) is observed. Future efforts should prioritize: discovery of conserved antigens, optimization of delivery platforms/adjuvants, and translational validation in pigs to achieve broad, durable immunity.

Keywords: Streptococcus suis, Subunit Vaccines, adjuvants, cross-protection, Vaccine delivery

Received: 06 Aug 2025; Accepted: 02 Sep 2025.

Copyright: © 2025 Fang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Lihua Fang, Shenzhen Longhua District Central Hospital, Shenzhen, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.